Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis

Overview of attention for article published in Journal of Translational Medicine, December 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#21 of 4,249)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

So far, Altmetric has seen 61 news stories from 45 outlets.

Generalised myasthenia gravis is a rare condition – but UCB’s Rystiggo enters a competitive market.

Biologic License Application (BLA) designated Priority Review by FDA and seeks approval for rozanolixizumab for the treatment…

News provided by UCB Jan 06, 2023, 7:00 AM ET Biologic License Application (BLA) designated Priority Review by FDA and seeks…

Biologic License Application (BLA) designated Priority Review by FDA and seeks approval for rozanolixizumab for the treatment…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 57 additional news stories.